12月20日,诺和诺德盘前股价一度大跌近30%,创下历史上最大单日跌幅。该公司发表一项新型减重药CagriSema的后期临床数据未能显著击败礼来公司现有的GLP-1药物替尔泊肽(商品名:穆峰达)的减重疗效。 最新数据显示,持续注射CagriSema 68周能够帮助肥胖患者平均减重22.7%。这一数据与礼来现有的替尔泊肽22.5%的减重疗效相差无几。诺和诺德此前预计,该药物可减重达25%。 当天...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.